{"ticker": {"uuid": "8cec622b-babf-4237-9cff-7bf5beb510ad", "symbol": "ALMS", "name": "Alumis Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Alumis | 4: Statement of changes in beneficial ownership of securities-10% Owner Foresite Capital Management VI LLC", "summary": "This document is a statement of changes in beneficial ownership of securities for Alumis, specifically involving a 10% owner, Foresite Capital Management VI LLC. Such statements are routinely filed with regulatory bodies to disclose significant changes in ownership by major share", "url": "https://www.moomoo.com/news/notice/306864019/alumis-4-statement-of-changes-in-beneficial-ownership-of-securities", "source_name": "Moomoo", "published_at": "2026-06-21T16:12:09", "published_display": "21 Jun 2026 16:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alumis Inc (ALMS) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "Alumis Inc (ALMS) currently has an earnings forecast score of 9.09, placing it favorably within the Biotechnology & Medical Research industry. Analysts have assigned an average price target of $18.00 for ALMS, with a majority recommending a \"Buy\" rating. The company's expected re", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-alms/earnings", "source_name": "TradingKey", "published_at": "2026-06-17T19:38:55", "published_display": "17 Jun 2026 19:38", "sentiment": "positive", "sentiment_pct": 70, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alumis Inc (ALMS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article provides a revenue breakdown for Alumis Inc (ALMS), detailing its business segments, regional revenue, and profit contribution. It notes that significant financial data for FY2025, including quarterly breakdowns, has not yet been disclosed by the company. The current", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-alms/revenue", "source_name": "TradingKey", "published_at": "2026-06-16T14:11:30", "published_display": "16 Jun 2026 14:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alumis (ALMS) Sees 10.3% Surge, Reaching $23.06", "summary": "Alumis Inc (ALMS) experienced a 10.3% stock surge, closing at $23.06, driven by positive market sentiment and investor interest in its biotechnology therapies. Despite a low GF Score\u2122 of 14/100 due to profitability concerns, the company exhibits strong financial stability with an", "url": "https://www.gurufocus.com/news/8914302/alumis-alms-sees-103-surge-reaching-2306?mobile=true", "source_name": "GuruFocus", "published_at": "2026-06-14T02:09:14", "published_display": "14 Jun 2026 02:09", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alumis Shares Surge 16% as Traders Eye New Drug Move", "summary": "Alumis Inc. (ALMS) shares jumped 15.55% to $24.15 on high volume as traders anticipate key clinical and regulatory milestones for its main drug, envudeucitinib. The late-stage biopharma company, which currently operates at a loss, is expecting Phase 2b LUMUS lupus data in Q3 2026", "url": "https://ts2.tech/en/alumis-shares-surge-16-as-traders-eye-new-drug-move/", "source_name": "TechStock\u00b2", "published_at": "2026-06-13T00:39:59", "published_display": "13 Jun 2026 00:39", "sentiment": "positive", "sentiment_pct": 72, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alumis | SCHEDULE 13D/A: Others", "summary": "This article consists solely of the word \"Document,\" indicating it is likely a placeholder or a very brief record of a filing or piece of content. Without additional information, it's impossible to provide further context or detail.", "url": "https://www.moomoo.com/news/notice/306864023/alumis-schedule-13d-a-others", "source_name": "Moomoo", "published_at": "2026-06-09T23:39:12", "published_display": "09 Jun 2026 23:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Has Alumis's Envudeucitinib Redefined Psoriasis Treatment", "summary": "Alumis's envudeucitinib, an oral TYK2 inhibitor, has shown strong Phase 3 results for plaque psoriasis, demonstrating high skin clearance rates and quality of life improvements. Its differentiated profile, including superior efficacy to apremilast and maximal 24-hour TYK2 inhibit", "url": "https://www.kavout.com/market-lens/has-alumis-s-envudeucitinib-redefined-psoriasis-treatment", "source_name": "Kavout", "published_at": "2026-05-30T02:09:50", "published_display": "30 May 2026 02:09", "sentiment": "positive", "sentiment_pct": 82, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Analyst Sentiment On Alumis (ALMS) Remains Strong Following Q1 Results And Envudeucitinib Pipeline Advancements", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxOSkNLUGZFVzhVN0oxTzdhLUJuMEdIVC1wNHA4S3NjQlB2TnFFbkhtREFmZXBjam1la3NrRmlRTkptNXQ0S2RrZXFJLTJNcHcwblE5dVRaNlU3S0VOOHdPUDZfQjlyNFRvSllWLTZrMWRKeldaRnJaaE1Ob19uSkNoLTAwYzVRVjRwdUZLX0ZseEFEWTQyNnB4ZEhqUE9RYkkzQlJmYw?oc=5", "source_name": "Market source", "published_at": "2026-05-29T07:00:00+00:00", "published_display": "29 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ALMS Stock Chart | ALUMIS INC (NASDAQ:ALMS)", "summary": "This article provides a stock chart for ALUMIS INC (NASDAQ: ALMS) from ChartMill.com. It shows the current stock price as 21.6 USD, indicating a 0.93% increase at market close on May 29, 2026. The article highlights various financial analysis tools available on the ChartMill plat", "url": "https://www.chartmill.com/stock/quote/ALMS/stock-chart", "source_name": "ChartMill", "published_at": "2026-05-29T07:09:08", "published_display": "29 May 2026 07:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alumis (ALMS) Chief Medical Officer exercises stock options for 26,852 shares", "summary": "Alumis Inc.'s Chief Medical Officer, Jorn Drappa, exercised stock options to acquire a total of 26,852 shares of common stock. These exercises, reported on May 22, 2026, involved two blocks of shares at strike prices of $5.06 and $8.84 per share. No open-market purchases or sales", "url": "https://www.stocktitan.net/sec-filings/ALMS/form-4-alumis-inc-insider-trading-activity-5177d5a10f12.html", "source_name": "Stock Titan", "published_at": "2026-05-27T23:10:18", "published_display": "27 May 2026 23:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "10 Under-the-Radar Stocks with Massive Upside for 2026", "summary": "This article highlights several under-the-radar stocks with massive upside potential for 2026, focusing on Alumis Inc. (NASDAQ:ALMS) as an example. Alumis Inc. has a 79.4% analyst consensus upside and has received multiple price target increases following positive Q1 results and ", "url": "https://www.insidermonkey.com/blog/10-under-the-radar-stocks-with-massive-upside-for-2026-1769445/4/", "source_name": "Insider Monkey", "published_at": "2026-05-27T20:10:18", "published_display": "27 May 2026 20:10", "sentiment": "positive", "sentiment_pct": 72, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TOWERVIEW LLC's Alumis Inc(ALMS) Holding History", "summary": "This article details TOWERVIEW LLC's holding history in Alumis Inc (ALMS). As of March 31, 2026, TOWERVIEW LLC holds 222,294 shares valued at $4.90 million, representing 3.16% of their portfolio. The firm has made 5 purchases and 1 sale of ALMS shares since Q2 2024, resulting in ", "url": "https://www.gurufocus.com/guru-portfolio/TOWERVIEW%20LLC/ALMS", "source_name": "GuruFocus", "published_at": "2026-05-27T19:39:28", "published_display": "27 May 2026 19:39", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look At Alumis (ALMS) Valuation After First Quarter 2026 Earnings Shift", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-26T07:00:00+00:00", "published_display": "26 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How Alumis\u2019 Revenue Slide but Smaller Per-Share Loss Will Impact Alumis (ALMS) Investors", "summary": "Alumis Inc. recently reported Q1 2026 results with a significant revenue drop from US$17.39 million to US$1.74 million but a narrowed net loss of US$93.05 million, down from US$98.96 million. Despite the revenue slide, the company reduced its basic loss per share to US$0.74 from ", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-alms/alumis/news/how-alumis-revenue-slide-but-smaller-per-share-loss-will-imp", "source_name": "Simply Wall Street", "published_at": "2026-05-25T00:09:04", "published_display": "25 May 2026 00:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alumis Analyst Ratings and Price Targets | NASDAQ:ALMS", "summary": "This article provides an overview of analyst ratings and price targets for Alumis Inc. (NASDAQ:ALMS). Based on 12 analysts, Alumis has a consensus price target of $36.73, with a high of $55 and a low of $14. The most recent analyst ratings suggest an implied 89.22% upside for the", "url": "https://www.benzinga.com/quote/ALMS/analyst-ratings", "source_name": "Benzinga", "published_at": "2026-05-23T04:09:04", "published_display": "23 May 2026 04:09", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Chardan Capital Maintains Alumis(ALMS.US) With Buy Rating, Raises Target Price to $40", "summary": "Chardan Capital has reiterated its Buy rating for Alumis (ALMS.US) and increased its target price to $40. This revision suggests a strong outlook from the firm regarding Alumis's future performance.", "url": "https://www.moomoo.com/news/post/70248131/chardan-capital-maintains-alumis-almsus-with-buy-rating-raises-target", "source_name": "Moomoo", "published_at": "2026-05-20T14:09:24", "published_display": "20 May 2026 14:09", "sentiment": "positive", "sentiment_pct": 72, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ALMS Maintained by Chardan Capital -- Price Target Raised to $40", "summary": "Chardan Capital analyst Janani Sundararajan has reaffirmed a 'Buy' rating for Alumis (ALMS) and increased the price target to $40.00 from $38.00, reflecting confidence in the company's growth potential despite its low GF Score\u2122 of 14/100. Alumis, a clinical-stage biopharmaceutica", "url": "https://www.gurufocus.com/news/8869464/alms-maintained-by-chardan-capital-price-target-raised-to-4000", "source_name": "GuruFocus", "published_at": "2026-05-19T14:08:42", "published_display": "19 May 2026 14:08", "sentiment": "positive", "sentiment_pct": 69, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 93, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alumis price target raised to $40 from $38 at Chardan", "summary": "Chardan has increased its price target for Alumis (ALMS) to $40 from $38, maintaining a Buy rating on the shares. This adjustment reflects updated pricing assumptions for envudeucitinib, minor changes in psoriasis penetration, and revised financial data following the company's fi", "url": "https://www.tipranks.com/news/the-fly/alumis-price-target-raised-to-40-from-38-at-chardan-thefly-news", "source_name": "TipRanks", "published_at": "2026-05-19T13:08:42", "published_display": "19 May 2026 13:08", "sentiment": "positive", "sentiment_pct": 75, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Chardan Raises Price Target on Alumis to $40 From $38, Keeps Buy Rating", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/chardan-raises-price-target-alumis-115915898.html", "source_name": "MT Newswires", "published_at": "2026-05-19T11:59:15+00:00", "published_display": "19 May 2026 11:59", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Assessing Alumis (ALMS) Valuation After Positive Phase 3 Envudeucitinib Data And Upcoming Regulatory Milestones", "summary": "Alumis (ALMS) stock is under scrutiny after reporting positive Phase 3 data for its oral TYK2 inhibitor envudeucitinib but also weaker Q1 2026 revenue. Despite recent short-term pullbacks, the stock has shown strong long-term momentum. The article questions whether Alumis is unde", "url": "https://www.sahmcapital.com/news/content/assessing-alumis-alms-valuation-after-positive-phase-3-envudeucitinib-data-and-upcoming-regulatory-milestones-2026-05-18", "source_name": "Sahm", "published_at": "2026-05-19T09:08:41", "published_display": "19 May 2026 09:08", "sentiment": "negative", "sentiment_pct": 39, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Alumis (ALMS) Trading Short-Term Revenue for a Leaner, More Focused Business Model?", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxPTlNKN0w3a3o5Tk5JQVRoRXdFaGhqaGNlZDB2Y0NVMWlOODNVWUtKaVBpUXMzd21kOEJNRldwYU5PSkVCVFl4bWliWjFuSVNHbWNlZXBmVHFtUTNVTHZSZ09GOGhOOEdFUWN6XzNWYl9yVEtnUDd6eHRkQkF0OU13Mmc0eEp2YnpIVTNGSzVPRlNsZVVDUjQwZnd5RQ?oc=5", "source_name": "Market source", "published_at": "2026-05-19T07:00:00+00:00", "published_display": "19 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[ARS] ALUMIS INC. SEC Filing", "summary": "This article reports on an ARS SEC filing by Alumis Inc. (ALMS) on May 18, 2026, at 04:29 PM. The filing is categorized with low impact and neutral sentiment. The article also provides recent news and SEC filings related to Alumis Inc., along with key stock data.", "url": "https://www.stocktitan.net/sec-filings/ALMS/ars-alumis-inc-sec-filing-956275cad20d.html", "source_name": "Stock Titan", "published_at": "2026-05-19T02:39:53", "published_display": "19 May 2026 02:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[DEF 14A] ALUMIS INC. Definitive Proxy Statement", "summary": "Alumis Inc. has filed a Definitive Proxy Statement (DEF 14A) for its 2026 Annual Meeting of Stockholders to be held virtually on June 30, 2026. Stockholders are asked to elect three Class II directors and ratify the appointment of PricewaterhouseCoopers LLP as the independent aud", "url": "https://www.stocktitan.net/sec-filings/ALMS/def-14a-alumis-inc-definitive-proxy-statement-b03eec7aad2a.html", "source_name": "Stock Titan", "published_at": "2026-05-19T01:38:57", "published_display": "19 May 2026 01:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ALUMIS INC. ($ALMS) CEO 2025 Pay Revealed | ALMS Stock News", "summary": "", "url": "https://news.google.com/rss/articles/CBMihwFBVV95cUxPRFQ5YWJlUUNKbmJqUlZteTVGN0VWV1JEWDE4a3lPZUNoeVJUOW1FVVpQLUJEOXRybFAtYUltOThYb1F2V3hISVBDd3B4aUo2YW9RWG1pc0I5akJHUlg4RUNVemNackMzdWktTjNGdXRNSVpPWEMxQ0pkMm1iQ2NjVkY4RFU5S0k?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-05-18T07:00:00+00:00", "published_display": "18 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alumis Stock Has Soared 400%. Cormorant Bought Another $8 Million Last Quarter", "summary": "", "url": "https://finance.yahoo.com/m/776ffd42-e119-3426-89b8-0a6110cd9dc3/alumis-stock-has-soared-400%25..html", "source_name": "Motley Fool", "published_at": "2026-05-17T18:33:40+00:00", "published_display": "17 May 2026 18:33", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cormorant Asset Management Acquires 313,645 Shares of Alumis in Q1 2026", "summary": "Cormorant Asset Management has acquired 313,645 shares of Alumis during Q1 2026, investing $7.84 million in the biotechnology company. This investment increased Cormorant's stake value in Alumis by $51.52 million and represents 4.37% of its 13F assets. Alumis shares have surged 4", "url": "https://www.indexbox.io/blog/cormorant-asset-management-acquires-313645-shares-of-alumis-in-q1-2026/", "source_name": "IndexBox", "published_at": "2026-05-17T19:09:26", "published_display": "17 May 2026 19:09", "sentiment": "positive", "sentiment_pct": 72, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Should Alumis\u2019 (ALMS) Envudeucitinib-Centric Strategy After Q1 Losses Require Action From Investors?", "summary": "Alumis Inc. (ALMS) reported Q1 2026 results with a net loss of US$93.05 million, but highlighted strong Phase 3 data for its oral TYK2 inhibitor envudeucitinib in plaque psoriasis. The company plans a New Drug Application in late 2026 for envudeucitinib and anticipates pivotal sy", "url": "https://www.sahmcapital.com/news/content/should-alumis-alms-envudeucitinib-centric-strategy-after-q1-losses-require-action-from-investors-2026-05-16", "source_name": "Sahm", "published_at": "2026-05-17T13:10:17", "published_display": "17 May 2026 13:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alumis (Nasdaq:ALMS) - Aktienanalyse", "summary": "Alumis Inc. (Nasdaq:ALMS) is a clinical-stage biopharmaceutical company focused on developing and commercializing drugs for autoimmune diseases. The company's stock is currently trading at US$22.04, with analysts estimating a fair value of US$40.1, indicating it is undervalued. R", "url": "https://simplywall.st/de/stocks/us/pharmaceuticals-biotech/nasdaq-alms/alumis", "source_name": "Simply Wall Street", "published_at": "2026-05-16T14:39:43", "published_display": "16 May 2026 14:39", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alumis Stock Is Up Over 300%. One Major Healthcare Investor Is Cutting Back", "summary": "", "url": "https://finance.yahoo.com/m/57f8007a-837d-3071-9902-8e6149055817/alumis-stock-is-up-over-300%25..html", "source_name": "Motley Fool", "published_at": "2026-05-15T22:56:41+00:00", "published_display": "15 May 2026 22:56", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "HC Wainwright & Co. downgrades Alumis (ALMS)", "summary": "This article reports that HC Wainwright & Co. has downgraded its rating for Alumis (ALMS). The specific details or reasons for the downgrade are not provided within the given content.", "url": "https://www.msn.com/en-us/money/topstocks/hc-wainwright-co-downgrades-alumis-alms/ar-AA23iAUk?ocid=finance-verthp-feeds", "source_name": "MSN", "published_at": "2026-05-15T23:38:59", "published_display": "15 May 2026 23:38", "sentiment": "negative", "sentiment_pct": 30, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Stifel reiterates Alumis stock rating on psoriasis trial data", "summary": "Stifel maintained a Buy rating and a $44.00 price target for Alumis Inc (ALMS) after the company's first-quarter 2026 update and positive Phase 3 data for its TYK2 inhibitor, envudeucitinib, in psoriasis. The firm highlighted that the data for envudeucitinib were comparable to or", "url": "https://m.investing.com/news/analyst-ratings/stifel-reiterates-alumis-stock-rating-on-psoriasis-trial-data-93CH-4692349?ampMode=1", "source_name": "Investing.com", "published_at": "2026-05-15T13:09:54", "published_display": "15 May 2026 13:09", "sentiment": "positive", "sentiment_pct": 69, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "This Alumis Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday", "summary": "This article details the top five analyst downgrades on Friday, May 15, 2026. Alumis Inc. (NASDAQ: ALMS) saw its rating cut from Buy to Neutral, while Tango Therapeutics (NASDAQ: TNGX), Viking Holdings (NYSE: VIK), Aardvark Therapeutics (NASDAQ: AARD), and A.O. Smith Corp (NYSE: ", "url": "https://www.benzinga.com/analyst-stock-ratings/downgrades/26/05/52594028/this-alumis-analyst-is-no-longer-bullish-here-are-top-5-downgrades-for-friday", "source_name": "Benzinga", "published_at": "2026-05-15T12:09:54", "published_display": "15 May 2026 12:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Guggenheim raises Alumis stock price target to $34 on psoriasis data", "summary": "Guggenheim has increased its price target for Alumis Inc (NASDAQ:ALMS) to $34 from $32 and maintained a Buy rating, following positive first-quarter earnings and promising clinical trial updates for its oral TYK2 inhibitor, envudeucitinib, in psoriasis. The company's stock has se", "url": "https://www.investing.com/news/analyst-ratings/guggenheim-raises-alumis-stock-price-target-to-34-on-psoriasis-data-93CH-4691972", "source_name": "Investing.com", "published_at": "2026-05-15T07:31:00", "published_display": "15 May 2026 07:31", "sentiment": "positive", "sentiment_pct": 87, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alumis psoriasis pill hits 68% PASI 90 in Phase 3 trial", "summary": "Alumis (NASDAQ: ALMS) reported its Q1 2026 financial results, including a net loss of $93.1 million and cash reserves of $569.5 million, which are expected to fund operations into Q4 2027. The company highlighted strong Phase 3 clinical data for its psoriasis treatment, envudeuci", "url": "https://www.stocktitan.net/news/ALMS/alumis-reports-first-quarter-2026-financial-results-and-highlights-n0baw1lbyb7o.html", "source_name": "Stock Titan", "published_at": "2026-05-14T20:40:52", "published_display": "14 May 2026 20:40", "sentiment": "positive", "sentiment_pct": 72, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Press Release: Alumis Reports First Quarter 2026 Financial Results and Highlights Recent Achievements", "summary": "The press release from Alumis reports the company's financial results for the first quarter of 2026 and highlights recent achievements. Additionally, it mentions Unity Software's fourth-quarter financial results, including a 35% year-over-year revenue increase to $609 million and", "url": "https://www.moomoo.com/news/post/70033056/press-release-alumis-reports-first-quarter-2026-financial-results-and?futusource=news_newspage_recommend", "source_name": "Moomoo", "published_at": "2026-05-14T20:09:05", "published_display": "14 May 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Envudeucitinib Phase 3 gains and Q1 2026 results for Alumis (NASDAQ: ALMS)", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxObVlHQi03MkNzXzFXUGZLUjJfaGkta1FhLS1KcmQ3bVNaenl4TEYxcHIwYVByWUZ3NWVycjNwdVBSb3JnaEdQSXNpeXNZeFFlWGNQU1JyVF9GdVdSNEpLMFUwTG9SVmd2a04zbkJwcnRESWM2Wl93SzhndkNJTE95QmYzeWhjXzFXbTdlcktBcW9zR3pIYXItR0R1bnIyUGFw?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look At Alumis (ALMS) Valuation After Revenue Drop And Narrowed Net Loss", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxQVXU1QndDaVFaQUc3T1VvRy02Z1E0TWxuSndUZ2pVd25IUWFQa3FmRWFCdjlFSE1JSVoxcmluZTg1WjNpcFNENHdrUFJuYnF4N2lLOGVZQzljTVZMaG0tRnBFMnBEZG16cFgzZVRPRVZwdlZUeGFkQUVHd0NBcjhzWDVyMll4WFZneW5SOUY0SnpSYUlIRDRrckMxOU1ZYUgt?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Is Alumis (ALMS) Stock Overvalued Now | Price at $22.31, Up 1.69% - Take Profit Levels", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxQbVNLY1lENUVsdGdxZDlkcnd6cWdZVUdfSWZmN2hibjN2ekJDcHhYSVF4OHg3TjVnSENKbnFSRzZNcWVVU2VPMUNuM3YyX2hFSWk1NEhBeVhRMElKcFh5c3dZSHFYSDlmSXVnekhrSmhhblBTdUhSa3NMdkhJMVJHazZLVW5pUlRZT3YwUXZ5RVVkVEN6UmNIWHJ1OXlWVWdlOVVVRlhWSkhFWU96?oc=5", "source_name": "lwvtexas.org", "published_at": "2026-04-08T07:00:00+00:00", "published_display": "08 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Alumis (ALMS) Is Down 5.8% After Positive Phase 3 Psoriasis Data And NDA Plans", "summary": "", "url": "https://news.google.com/rss/articles/CBMikAFBVV95cUxQbHN0dk9fdTM2M0J2el8yWWxZV00yVlZpa0lRTnFwZm96dXRqQnZkRmdfUzl0RjN0SGlSOF9uSEItd3RaV2l4SDBOdktrZVpJd1UzWUY5clY3NmJEOFZFcEY3Z01vV1Z0emgyZ1c2aHVSclZNQlFyRTlfY1VFdEI0Q0F4MmpsUjZZVVFiVEl4UXk?oc=5", "source_name": "Market source", "published_at": "2026-04-04T07:00:00+00:00", "published_display": "04 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Foresite entities move ALUMIS (ALMS) shares in pro rata in-kind distributions", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxNeFBsbG1iczVKUWRYOW1vOHhfSEhWTVYwbVdXTC11dHQxRHFlekhOZzZZU2RZc1RNS082ZU12UVpTRFZTR0ZvTnpneEk5NmhFR0t0YTRUYzFRYlBfbHliWmpIMzJ6bVpSV0x6ZWFncV9tdmN3bEJLQXZDNWRSendyaWRNQmVCdTljZVRNRnR4dEFhWkdfMHlxSXhOSGIwSUZwVmIzaThiaw?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-03T07:00:00+00:00", "published_display": "03 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alumis (ALMS) insider-linked entities shift 4.1M shares via in-kind distributions", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxPaDRNZXNEX3dDWHdyRVpyZkhyR2lub0tUdklSUUhXT1lEZEpZQVY0VVpjeW1OdGZfdUd1S0FvZWt0Zk1JZDdiMmZtR2tuNnJhaFZnSkZPOFNkRFM1NlVtLUdnVVJ2eHhTdzNyaUR6d3ExUzJldlY5VjQ1bGJmY3otYXhlSm1Cakg1RkU0akNTS1psSHM5VmR6S2tRRmRqY1ZoRkJjT29jRQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-03T07:00:00+00:00", "published_display": "03 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Phase 3 win positions Alumis (NASDAQ: ALMS) psoriasis pill for 2026 NDA", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxOZjItZFctUFJhWFF0bzNPeUFjRGZZMlRKbnFpcVE3ZFFjTVdxMmt5a3U2cmFZcEJCQUpia0ZSMGJnQ1R6SS1lM18yZkNGOVN6NnlyQ1JvYngwZ3BsSWtPazVNWTIxTC11Q2tPem5JVjVxcDJtSjZpNm95bEhKaHQ3V0MwU2x3MVczbVhnNDczVU00U1ZwdUN1N0I2WWhnYVRl?oc=5", "source_name": "Stock Titan", "published_at": "2026-03-30T07:00:00+00:00", "published_display": "30 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxNZXlTZHFHZVNxMktqZ0hVNURmdE1hUFpZZnlfdEVhMnVla2EyTWN6b2YwNkVhNllxUy1Bczl2a0ZUNk04Q3oyTEZSajdpMnFDVXJfRTlfLUdHQ05uS3FQZkhNWkJ0MDFENDJvRXR0ZGV1RDlYVmdWem96V29NeTg4YWRZWGNoMzM1emRoSExJbXdwZnJIWHpsYjVnT0FQVHZtUW5iVg?oc=5", "source_name": "Market source", "published_at": "2026-03-30T07:00:00+00:00", "published_display": "30 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Alumis (ALMS) Q4 Loss Of US$92.9 Million Tests Bullish Growth Narrative", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-03-20T07:00:00+00:00", "published_display": "20 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A psoriasis pill hit late-stage goals; Alumis plans U.S. filing in 2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxPRks2MlJ2LWZNcXZjX1pRQ0I4OXUzck5SeXVIWE1ObFViZTUtdkZJeVctdjE0NTBrMWNHQkZTUUZBT0tzdlNzMHlJNU5DS2NTVHA3c0tEM2RBMlM1ejRqMnJuQnNueFdTenltVXNQZW1NWHpmc25VbE55QTBmbW42NzBvc0hIRXhLQ0FuazJSdzlaa2RJcXZIUjFXcDJoYjVCWl9TSUJSRmZ4XzFCdVVOTEEyOWN4UW10R1I0bzJkLW8?oc=5", "source_name": "Stock Titan", "published_at": "2026-03-19T07:00:00+00:00", "published_display": "19 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Assessing Alumis (ALMS) Valuation After A Strong Multi\u2011Month Share Price Run", "summary": "", "url": "https://news.google.com/rss/articles/CBMijAFBVV95cUxNeW5zNW5sUlF4SHJTVWtkVVBMc3k1ZHItclFDcnlxV3VSaTA0NUdhcW9BdUdvcXNCNS16T3VqbDNwd0o2MmRJTDJtN2VlZkI3emR3bHFHemxRb1d0VVc5SmRVb1RZdldFYTducG4wWndTRWxDUUxQRFN2WG1iT2lTcmNaUjdEOUNGdXhlVg?oc=5", "source_name": "Market source", "published_at": "2026-03-10T07:00:00+00:00", "published_display": "10 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alumis (ALMS) Valuation Check After Strong Multi\u2011Month Share Price Momentum", "summary": "", "url": "https://news.google.com/rss/articles/CBMihwFBVV95cUxObTV2U1VJSkRCaGZfWHlSM0VTdEdWNzFtZl8tNmxWQW11TWVFSDBUVjNhdWZ2OHBLNzdDUFd4UmJhdWRscGJEeENJQTBZLXBlRldJUU1Ya2VKSHluM2k5TEtvdTNXNHZodVVvQkxyX1ktMXpqSDFBV3laQnA1NVdkQkZSekVHWjg?oc=5", "source_name": "Market source", "published_at": "2026-02-07T08:00:00+00:00", "published_display": "07 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alumis Ownership Shifts As Shelf Filing And Conferences Shape Outlook", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-02-06T08:00:00+00:00", "published_display": "06 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alumis (ALMS) Is Up 22.0% After Phase 3 Psoriasis Win And $300 Million Equity Raise", "summary": "", "url": "https://news.google.com/rss/articles/CBMid0FVX3lxTFBIc1loYjE5bS0wZUZKa3VkSVdKX0dvNGFkRVI5UkhHSzBlYks3WnZ6SFFoVzd3dktla1FoSm5LdHR1Q2xOSHFSOGlDQWM4VUdqejV5Mkd6YS04YVZnZXRVNlpaMVhwSjRjNm9maDF1UHJGQ1Z6UHRF?oc=5", "source_name": "Market source", "published_at": "2026-01-18T08:00:00+00:00", "published_display": "18 Jan 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alumis Inc. Stock (ALMS) Opinions on Phase 3 Trial Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxNMVZQeHQ4R2hubjQyWFdOcWE0R3NkSzdaNG44NEVXcTdMc0x2bWRpeG5wY3haamMyZDJOVzBsd05GdE1vSTZXaXpXRm51OFlCUl92a1FHOWF2LXFwSlk4MXpHV1R1Q0dJaVFFUERKbVdnZkFrMXFEZ1lRSlQ2ZmducHEzcnJ6dFdXcnV1UTd4ZDVkbGV3bjAzcjZZaw?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-01-13T08:00:00+00:00", "published_display": "13 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Assessing Alumis (ALMS) Valuation After Positive Phase 3 Psoriasis Data And Strong Share Price Momentum", "summary": "", "url": "https://news.google.com/rss/articles/CBMijwFBVV95cUxQZ1o3RFdlRWRtdmhFYWxrQWREREtiZ21sREc3MF9SMmlMTlhmSWV2SVZKcDU5YzZVN2hES0Z2UzNrWXZobVlSbXJfV3h4aUZJSDllcGd6amZTTE03WnBza3d2RU1yM19aZ2pzMjZoXzYwY1ZpazRFZUtpa25fWjlDZEJyWDBGZXMzQzh6S2JwUQ?oc=5", "source_name": "Market source", "published_at": "2026-01-08T08:00:00+00:00", "published_display": "08 Jan 2026 08:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Alumis Stock Spiked Almost 100% Yesterday", "summary": "", "url": "https://news.google.com/rss/articles/CBMijwFBVV95cUxPdlVibDhuMVl3WEd0dEdZekltSUZLcjVENXUyeTZpV09xTUhnWDBFU2pReEtOZ0tNdE1Kd3A2SHlFU09leEc5MjVlbmdxeldDUFVTNFlHSWxEbGJ3SzRjb3BsN3B3LWtLUTNvM3I0amY1cEkwTkFkS1c4R2xPblRyVnc0TlRZckF3ZUd4cHBCRQ?oc=5", "source_name": "TIKR.com", "published_at": "2026-01-07T08:00:00+00:00", "published_display": "07 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alumis Stock Hits Record High As Wall Street Cheers Phase 3 Psoriasis \u2018Win\u2019 \u2014 Analysts See Best-In-Class Potential", "summary": "", "url": "https://news.google.com/rss/articles/CBMihAJBVV95cUxPU2txZzUtT2tLWGgxVThtZU1wU1BGMDRic0JUUmxwbEtfdTdpcHJrM21Sd2xTZWhKbC1Hc1hsVVI1Z0EwWGZZZ3VqbS01X1VDMUQzRy1XVEptZm82bl9fV2pDajFZSlEzLXJKU212WUtzd0ItN2RRcEN6VG8xclhSc0R2ajZ3cE5Ha2VhR0xNQS0xbmVjTW41N09RVWVhLWNzRUt1bG54VE9TVUdWTHFQMTV6b25rb0xzTXBHVld3Wjd4ZXhZY1l5SDAyOXp0aXpFLTNsck5SSlRYcW1mZDVMRDJXbTBTVWtndDlSMVA3VmYxVlpIU0FTS1p6NHFrTnlGdUdiUw?oc=5", "source_name": "Stocktwits", "published_at": "2026-01-06T08:00:00+00:00", "published_display": "06 Jan 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biotech Alumis plans $175M stock sale in new public offering", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxQYVNEc3F5TXZfN3g5U2lIZnRJQUZlSXB5WS1GaWNxX1RQakR3QTVFbGJnX1F2NGs1RzBsYUF1bVJUMFRLeE1JTUU3b1REZk16SjRHXzE2RW9PUVY3Y3FKTmVodWdLQXhyZzQ1aVMtNnIwTWxHa3lybkk0WTM5TmtVMVlRVHI3RE9xOUpNbHlWMWRmc05zT193Z0FSMlhwbW9GN3RSdW9xYk1Xdw?oc=5", "source_name": "Stock Titan", "published_at": "2026-01-06T08:00:00+00:00", "published_display": "06 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "With EPS Growth And More, Puma Biotechnology (NASDAQ:PBYI) Makes An Interesting Case", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-12-09T08:00:00+00:00", "published_display": "09 Dec 2025 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "by_tier": {"direct": [{"title": "Alumis | 4: Statement of changes in beneficial ownership of securities-10% Owner Foresite Capital Management VI LLC", "summary": "This document is a statement of changes in beneficial ownership of securities for Alumis, specifically involving a 10% owner, Foresite Capital Management VI LLC. Such statements are routinely filed with regulatory bodies to disclose significant changes in ownership by major share", "url": "https://www.moomoo.com/news/notice/306864019/alumis-4-statement-of-changes-in-beneficial-ownership-of-securities", "source_name": "Moomoo", "published_at": "2026-06-21T16:12:09", "published_display": "21 Jun 2026 16:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alumis Inc (ALMS) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "Alumis Inc (ALMS) currently has an earnings forecast score of 9.09, placing it favorably within the Biotechnology & Medical Research industry. Analysts have assigned an average price target of $18.00 for ALMS, with a majority recommending a \"Buy\" rating. The company's expected re", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-alms/earnings", "source_name": "TradingKey", "published_at": "2026-06-17T19:38:55", "published_display": "17 Jun 2026 19:38", "sentiment": "positive", "sentiment_pct": 70, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alumis Inc (ALMS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article provides a revenue breakdown for Alumis Inc (ALMS), detailing its business segments, regional revenue, and profit contribution. It notes that significant financial data for FY2025, including quarterly breakdowns, has not yet been disclosed by the company. The current", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-alms/revenue", "source_name": "TradingKey", "published_at": "2026-06-16T14:11:30", "published_display": "16 Jun 2026 14:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alumis (ALMS) Sees 10.3% Surge, Reaching $23.06", "summary": "Alumis Inc (ALMS) experienced a 10.3% stock surge, closing at $23.06, driven by positive market sentiment and investor interest in its biotechnology therapies. Despite a low GF Score\u2122 of 14/100 due to profitability concerns, the company exhibits strong financial stability with an", "url": "https://www.gurufocus.com/news/8914302/alumis-alms-sees-103-surge-reaching-2306?mobile=true", "source_name": "GuruFocus", "published_at": "2026-06-14T02:09:14", "published_display": "14 Jun 2026 02:09", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alumis Shares Surge 16% as Traders Eye New Drug Move", "summary": "Alumis Inc. (ALMS) shares jumped 15.55% to $24.15 on high volume as traders anticipate key clinical and regulatory milestones for its main drug, envudeucitinib. The late-stage biopharma company, which currently operates at a loss, is expecting Phase 2b LUMUS lupus data in Q3 2026", "url": "https://ts2.tech/en/alumis-shares-surge-16-as-traders-eye-new-drug-move/", "source_name": "TechStock\u00b2", "published_at": "2026-06-13T00:39:59", "published_display": "13 Jun 2026 00:39", "sentiment": "positive", "sentiment_pct": 72, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alumis | SCHEDULE 13D/A: Others", "summary": "This article consists solely of the word \"Document,\" indicating it is likely a placeholder or a very brief record of a filing or piece of content. Without additional information, it's impossible to provide further context or detail.", "url": "https://www.moomoo.com/news/notice/306864023/alumis-schedule-13d-a-others", "source_name": "Moomoo", "published_at": "2026-06-09T23:39:12", "published_display": "09 Jun 2026 23:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Has Alumis's Envudeucitinib Redefined Psoriasis Treatment", "summary": "Alumis's envudeucitinib, an oral TYK2 inhibitor, has shown strong Phase 3 results for plaque psoriasis, demonstrating high skin clearance rates and quality of life improvements. Its differentiated profile, including superior efficacy to apremilast and maximal 24-hour TYK2 inhibit", "url": "https://www.kavout.com/market-lens/has-alumis-s-envudeucitinib-redefined-psoriasis-treatment", "source_name": "Kavout", "published_at": "2026-05-30T02:09:50", "published_display": "30 May 2026 02:09", "sentiment": "positive", "sentiment_pct": 82, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Analyst Sentiment On Alumis (ALMS) Remains Strong Following Q1 Results And Envudeucitinib Pipeline Advancements", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxOSkNLUGZFVzhVN0oxTzdhLUJuMEdIVC1wNHA4S3NjQlB2TnFFbkhtREFmZXBjam1la3NrRmlRTkptNXQ0S2RrZXFJLTJNcHcwblE5dVRaNlU3S0VOOHdPUDZfQjlyNFRvSllWLTZrMWRKeldaRnJaaE1Ob19uSkNoLTAwYzVRVjRwdUZLX0ZseEFEWTQyNnB4ZEhqUE9RYkkzQlJmYw?oc=5", "source_name": "Market source", "published_at": "2026-05-29T07:00:00+00:00", "published_display": "29 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ALMS Stock Chart | ALUMIS INC (NASDAQ:ALMS)", "summary": "This article provides a stock chart for ALUMIS INC (NASDAQ: ALMS) from ChartMill.com. It shows the current stock price as 21.6 USD, indicating a 0.93% increase at market close on May 29, 2026. The article highlights various financial analysis tools available on the ChartMill plat", "url": "https://www.chartmill.com/stock/quote/ALMS/stock-chart", "source_name": "ChartMill", "published_at": "2026-05-29T07:09:08", "published_display": "29 May 2026 07:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alumis (ALMS) Chief Medical Officer exercises stock options for 26,852 shares", "summary": "Alumis Inc.'s Chief Medical Officer, Jorn Drappa, exercised stock options to acquire a total of 26,852 shares of common stock. These exercises, reported on May 22, 2026, involved two blocks of shares at strike prices of $5.06 and $8.84 per share. No open-market purchases or sales", "url": "https://www.stocktitan.net/sec-filings/ALMS/form-4-alumis-inc-insider-trading-activity-5177d5a10f12.html", "source_name": "Stock Titan", "published_at": "2026-05-27T23:10:18", "published_display": "27 May 2026 23:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "10 Under-the-Radar Stocks with Massive Upside for 2026", "summary": "This article highlights several under-the-radar stocks with massive upside potential for 2026, focusing on Alumis Inc. (NASDAQ:ALMS) as an example. Alumis Inc. has a 79.4% analyst consensus upside and has received multiple price target increases following positive Q1 results and ", "url": "https://www.insidermonkey.com/blog/10-under-the-radar-stocks-with-massive-upside-for-2026-1769445/4/", "source_name": "Insider Monkey", "published_at": "2026-05-27T20:10:18", "published_display": "27 May 2026 20:10", "sentiment": "positive", "sentiment_pct": 72, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TOWERVIEW LLC's Alumis Inc(ALMS) Holding History", "summary": "This article details TOWERVIEW LLC's holding history in Alumis Inc (ALMS). As of March 31, 2026, TOWERVIEW LLC holds 222,294 shares valued at $4.90 million, representing 3.16% of their portfolio. The firm has made 5 purchases and 1 sale of ALMS shares since Q2 2024, resulting in ", "url": "https://www.gurufocus.com/guru-portfolio/TOWERVIEW%20LLC/ALMS", "source_name": "GuruFocus", "published_at": "2026-05-27T19:39:28", "published_display": "27 May 2026 19:39", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look At Alumis (ALMS) Valuation After First Quarter 2026 Earnings Shift", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-26T07:00:00+00:00", "published_display": "26 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How Alumis\u2019 Revenue Slide but Smaller Per-Share Loss Will Impact Alumis (ALMS) Investors", "summary": "Alumis Inc. recently reported Q1 2026 results with a significant revenue drop from US$17.39 million to US$1.74 million but a narrowed net loss of US$93.05 million, down from US$98.96 million. Despite the revenue slide, the company reduced its basic loss per share to US$0.74 from ", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-alms/alumis/news/how-alumis-revenue-slide-but-smaller-per-share-loss-will-imp", "source_name": "Simply Wall Street", "published_at": "2026-05-25T00:09:04", "published_display": "25 May 2026 00:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alumis Analyst Ratings and Price Targets | NASDAQ:ALMS", "summary": "This article provides an overview of analyst ratings and price targets for Alumis Inc. (NASDAQ:ALMS). Based on 12 analysts, Alumis has a consensus price target of $36.73, with a high of $55 and a low of $14. The most recent analyst ratings suggest an implied 89.22% upside for the", "url": "https://www.benzinga.com/quote/ALMS/analyst-ratings", "source_name": "Benzinga", "published_at": "2026-05-23T04:09:04", "published_display": "23 May 2026 04:09", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Chardan Capital Maintains Alumis(ALMS.US) With Buy Rating, Raises Target Price to $40", "summary": "Chardan Capital has reiterated its Buy rating for Alumis (ALMS.US) and increased its target price to $40. This revision suggests a strong outlook from the firm regarding Alumis's future performance.", "url": "https://www.moomoo.com/news/post/70248131/chardan-capital-maintains-alumis-almsus-with-buy-rating-raises-target", "source_name": "Moomoo", "published_at": "2026-05-20T14:09:24", "published_display": "20 May 2026 14:09", "sentiment": "positive", "sentiment_pct": 72, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ALMS Maintained by Chardan Capital -- Price Target Raised to $40", "summary": "Chardan Capital analyst Janani Sundararajan has reaffirmed a 'Buy' rating for Alumis (ALMS) and increased the price target to $40.00 from $38.00, reflecting confidence in the company's growth potential despite its low GF Score\u2122 of 14/100. Alumis, a clinical-stage biopharmaceutica", "url": "https://www.gurufocus.com/news/8869464/alms-maintained-by-chardan-capital-price-target-raised-to-4000", "source_name": "GuruFocus", "published_at": "2026-05-19T14:08:42", "published_display": "19 May 2026 14:08", "sentiment": "positive", "sentiment_pct": 69, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 93, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alumis price target raised to $40 from $38 at Chardan", "summary": "Chardan has increased its price target for Alumis (ALMS) to $40 from $38, maintaining a Buy rating on the shares. This adjustment reflects updated pricing assumptions for envudeucitinib, minor changes in psoriasis penetration, and revised financial data following the company's fi", "url": "https://www.tipranks.com/news/the-fly/alumis-price-target-raised-to-40-from-38-at-chardan-thefly-news", "source_name": "TipRanks", "published_at": "2026-05-19T13:08:42", "published_display": "19 May 2026 13:08", "sentiment": "positive", "sentiment_pct": 75, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Chardan Raises Price Target on Alumis to $40 From $38, Keeps Buy Rating", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/chardan-raises-price-target-alumis-115915898.html", "source_name": "MT Newswires", "published_at": "2026-05-19T11:59:15+00:00", "published_display": "19 May 2026 11:59", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Assessing Alumis (ALMS) Valuation After Positive Phase 3 Envudeucitinib Data And Upcoming Regulatory Milestones", "summary": "Alumis (ALMS) stock is under scrutiny after reporting positive Phase 3 data for its oral TYK2 inhibitor envudeucitinib but also weaker Q1 2026 revenue. Despite recent short-term pullbacks, the stock has shown strong long-term momentum. The article questions whether Alumis is unde", "url": "https://www.sahmcapital.com/news/content/assessing-alumis-alms-valuation-after-positive-phase-3-envudeucitinib-data-and-upcoming-regulatory-milestones-2026-05-18", "source_name": "Sahm", "published_at": "2026-05-19T09:08:41", "published_display": "19 May 2026 09:08", "sentiment": "negative", "sentiment_pct": 39, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Alumis (ALMS) Trading Short-Term Revenue for a Leaner, More Focused Business Model?", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxPTlNKN0w3a3o5Tk5JQVRoRXdFaGhqaGNlZDB2Y0NVMWlOODNVWUtKaVBpUXMzd21kOEJNRldwYU5PSkVCVFl4bWliWjFuSVNHbWNlZXBmVHFtUTNVTHZSZ09GOGhOOEdFUWN6XzNWYl9yVEtnUDd6eHRkQkF0OU13Mmc0eEp2YnpIVTNGSzVPRlNsZVVDUjQwZnd5RQ?oc=5", "source_name": "Market source", "published_at": "2026-05-19T07:00:00+00:00", "published_display": "19 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[ARS] ALUMIS INC. SEC Filing", "summary": "This article reports on an ARS SEC filing by Alumis Inc. (ALMS) on May 18, 2026, at 04:29 PM. The filing is categorized with low impact and neutral sentiment. The article also provides recent news and SEC filings related to Alumis Inc., along with key stock data.", "url": "https://www.stocktitan.net/sec-filings/ALMS/ars-alumis-inc-sec-filing-956275cad20d.html", "source_name": "Stock Titan", "published_at": "2026-05-19T02:39:53", "published_display": "19 May 2026 02:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[DEF 14A] ALUMIS INC. Definitive Proxy Statement", "summary": "Alumis Inc. has filed a Definitive Proxy Statement (DEF 14A) for its 2026 Annual Meeting of Stockholders to be held virtually on June 30, 2026. Stockholders are asked to elect three Class II directors and ratify the appointment of PricewaterhouseCoopers LLP as the independent aud", "url": "https://www.stocktitan.net/sec-filings/ALMS/def-14a-alumis-inc-definitive-proxy-statement-b03eec7aad2a.html", "source_name": "Stock Titan", "published_at": "2026-05-19T01:38:57", "published_display": "19 May 2026 01:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ALUMIS INC. ($ALMS) CEO 2025 Pay Revealed | ALMS Stock News", "summary": "", "url": "https://news.google.com/rss/articles/CBMihwFBVV95cUxPRFQ5YWJlUUNKbmJqUlZteTVGN0VWV1JEWDE4a3lPZUNoeVJUOW1FVVpQLUJEOXRybFAtYUltOThYb1F2V3hISVBDd3B4aUo2YW9RWG1pc0I5akJHUlg4RUNVemNackMzdWktTjNGdXRNSVpPWEMxQ0pkMm1iQ2NjVkY4RFU5S0k?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-05-18T07:00:00+00:00", "published_display": "18 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alumis Stock Has Soared 400%. Cormorant Bought Another $8 Million Last Quarter", "summary": "", "url": "https://finance.yahoo.com/m/776ffd42-e119-3426-89b8-0a6110cd9dc3/alumis-stock-has-soared-400%25..html", "source_name": "Motley Fool", "published_at": "2026-05-17T18:33:40+00:00", "published_display": "17 May 2026 18:33", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cormorant Asset Management Acquires 313,645 Shares of Alumis in Q1 2026", "summary": "Cormorant Asset Management has acquired 313,645 shares of Alumis during Q1 2026, investing $7.84 million in the biotechnology company. This investment increased Cormorant's stake value in Alumis by $51.52 million and represents 4.37% of its 13F assets. Alumis shares have surged 4", "url": "https://www.indexbox.io/blog/cormorant-asset-management-acquires-313645-shares-of-alumis-in-q1-2026/", "source_name": "IndexBox", "published_at": "2026-05-17T19:09:26", "published_display": "17 May 2026 19:09", "sentiment": "positive", "sentiment_pct": 72, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Should Alumis\u2019 (ALMS) Envudeucitinib-Centric Strategy After Q1 Losses Require Action From Investors?", "summary": "Alumis Inc. (ALMS) reported Q1 2026 results with a net loss of US$93.05 million, but highlighted strong Phase 3 data for its oral TYK2 inhibitor envudeucitinib in plaque psoriasis. The company plans a New Drug Application in late 2026 for envudeucitinib and anticipates pivotal sy", "url": "https://www.sahmcapital.com/news/content/should-alumis-alms-envudeucitinib-centric-strategy-after-q1-losses-require-action-from-investors-2026-05-16", "source_name": "Sahm", "published_at": "2026-05-17T13:10:17", "published_display": "17 May 2026 13:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alumis (Nasdaq:ALMS) - Aktienanalyse", "summary": "Alumis Inc. (Nasdaq:ALMS) is a clinical-stage biopharmaceutical company focused on developing and commercializing drugs for autoimmune diseases. The company's stock is currently trading at US$22.04, with analysts estimating a fair value of US$40.1, indicating it is undervalued. R", "url": "https://simplywall.st/de/stocks/us/pharmaceuticals-biotech/nasdaq-alms/alumis", "source_name": "Simply Wall Street", "published_at": "2026-05-16T14:39:43", "published_display": "16 May 2026 14:39", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alumis Stock Is Up Over 300%. One Major Healthcare Investor Is Cutting Back", "summary": "", "url": "https://finance.yahoo.com/m/57f8007a-837d-3071-9902-8e6149055817/alumis-stock-is-up-over-300%25..html", "source_name": "Motley Fool", "published_at": "2026-05-15T22:56:41+00:00", "published_display": "15 May 2026 22:56", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "HC Wainwright & Co. downgrades Alumis (ALMS)", "summary": "This article reports that HC Wainwright & Co. has downgraded its rating for Alumis (ALMS). The specific details or reasons for the downgrade are not provided within the given content.", "url": "https://www.msn.com/en-us/money/topstocks/hc-wainwright-co-downgrades-alumis-alms/ar-AA23iAUk?ocid=finance-verthp-feeds", "source_name": "MSN", "published_at": "2026-05-15T23:38:59", "published_display": "15 May 2026 23:38", "sentiment": "negative", "sentiment_pct": 30, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Stifel reiterates Alumis stock rating on psoriasis trial data", "summary": "Stifel maintained a Buy rating and a $44.00 price target for Alumis Inc (ALMS) after the company's first-quarter 2026 update and positive Phase 3 data for its TYK2 inhibitor, envudeucitinib, in psoriasis. The firm highlighted that the data for envudeucitinib were comparable to or", "url": "https://m.investing.com/news/analyst-ratings/stifel-reiterates-alumis-stock-rating-on-psoriasis-trial-data-93CH-4692349?ampMode=1", "source_name": "Investing.com", "published_at": "2026-05-15T13:09:54", "published_display": "15 May 2026 13:09", "sentiment": "positive", "sentiment_pct": 69, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "This Alumis Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday", "summary": "This article details the top five analyst downgrades on Friday, May 15, 2026. Alumis Inc. (NASDAQ: ALMS) saw its rating cut from Buy to Neutral, while Tango Therapeutics (NASDAQ: TNGX), Viking Holdings (NYSE: VIK), Aardvark Therapeutics (NASDAQ: AARD), and A.O. Smith Corp (NYSE: ", "url": "https://www.benzinga.com/analyst-stock-ratings/downgrades/26/05/52594028/this-alumis-analyst-is-no-longer-bullish-here-are-top-5-downgrades-for-friday", "source_name": "Benzinga", "published_at": "2026-05-15T12:09:54", "published_display": "15 May 2026 12:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Guggenheim raises Alumis stock price target to $34 on psoriasis data", "summary": "Guggenheim has increased its price target for Alumis Inc (NASDAQ:ALMS) to $34 from $32 and maintained a Buy rating, following positive first-quarter earnings and promising clinical trial updates for its oral TYK2 inhibitor, envudeucitinib, in psoriasis. The company's stock has se", "url": "https://www.investing.com/news/analyst-ratings/guggenheim-raises-alumis-stock-price-target-to-34-on-psoriasis-data-93CH-4691972", "source_name": "Investing.com", "published_at": "2026-05-15T07:31:00", "published_display": "15 May 2026 07:31", "sentiment": "positive", "sentiment_pct": 87, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alumis psoriasis pill hits 68% PASI 90 in Phase 3 trial", "summary": "Alumis (NASDAQ: ALMS) reported its Q1 2026 financial results, including a net loss of $93.1 million and cash reserves of $569.5 million, which are expected to fund operations into Q4 2027. The company highlighted strong Phase 3 clinical data for its psoriasis treatment, envudeuci", "url": "https://www.stocktitan.net/news/ALMS/alumis-reports-first-quarter-2026-financial-results-and-highlights-n0baw1lbyb7o.html", "source_name": "Stock Titan", "published_at": "2026-05-14T20:40:52", "published_display": "14 May 2026 20:40", "sentiment": "positive", "sentiment_pct": 72, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Press Release: Alumis Reports First Quarter 2026 Financial Results and Highlights Recent Achievements", "summary": "The press release from Alumis reports the company's financial results for the first quarter of 2026 and highlights recent achievements. Additionally, it mentions Unity Software's fourth-quarter financial results, including a 35% year-over-year revenue increase to $609 million and", "url": "https://www.moomoo.com/news/post/70033056/press-release-alumis-reports-first-quarter-2026-financial-results-and?futusource=news_newspage_recommend", "source_name": "Moomoo", "published_at": "2026-05-14T20:09:05", "published_display": "14 May 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Envudeucitinib Phase 3 gains and Q1 2026 results for Alumis (NASDAQ: ALMS)", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxObVlHQi03MkNzXzFXUGZLUjJfaGkta1FhLS1KcmQ3bVNaenl4TEYxcHIwYVByWUZ3NWVycjNwdVBSb3JnaEdQSXNpeXNZeFFlWGNQU1JyVF9GdVdSNEpLMFUwTG9SVmd2a04zbkJwcnRESWM2Wl93SzhndkNJTE95QmYzeWhjXzFXbTdlcktBcW9zR3pIYXItR0R1bnIyUGFw?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look At Alumis (ALMS) Valuation After Revenue Drop And Narrowed Net Loss", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxQVXU1QndDaVFaQUc3T1VvRy02Z1E0TWxuSndUZ2pVd25IUWFQa3FmRWFCdjlFSE1JSVoxcmluZTg1WjNpcFNENHdrUFJuYnF4N2lLOGVZQzljTVZMaG0tRnBFMnBEZG16cFgzZVRPRVZwdlZUeGFkQUVHd0NBcjhzWDVyMll4WFZneW5SOUY0SnpSYUlIRDRrckMxOU1ZYUgt?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Alumis (ALMS) Stock Overvalued Now | Price at $22.31, Up 1.69% - Take Profit Levels", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxQbVNLY1lENUVsdGdxZDlkcnd6cWdZVUdfSWZmN2hibjN2ekJDcHhYSVF4OHg3TjVnSENKbnFSRzZNcWVVU2VPMUNuM3YyX2hFSWk1NEhBeVhRMElKcFh5c3dZSHFYSDlmSXVnekhrSmhhblBTdUhSa3NMdkhJMVJHazZLVW5pUlRZT3YwUXZ5RVVkVEN6UmNIWHJ1OXlWVWdlOVVVRlhWSkhFWU96?oc=5", "source_name": "lwvtexas.org", "published_at": "2026-04-08T07:00:00+00:00", "published_display": "08 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Alumis (ALMS) Is Down 5.8% After Positive Phase 3 Psoriasis Data And NDA Plans", "summary": "", "url": "https://news.google.com/rss/articles/CBMikAFBVV95cUxQbHN0dk9fdTM2M0J2el8yWWxZV00yVlZpa0lRTnFwZm96dXRqQnZkRmdfUzl0RjN0SGlSOF9uSEItd3RaV2l4SDBOdktrZVpJd1UzWUY5clY3NmJEOFZFcEY3Z01vV1Z0emgyZ1c2aHVSclZNQlFyRTlfY1VFdEI0Q0F4MmpsUjZZVVFiVEl4UXk?oc=5", "source_name": "Market source", "published_at": "2026-04-04T07:00:00+00:00", "published_display": "04 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Foresite entities move ALUMIS (ALMS) shares in pro rata in-kind distributions", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxNeFBsbG1iczVKUWRYOW1vOHhfSEhWTVYwbVdXTC11dHQxRHFlekhOZzZZU2RZc1RNS082ZU12UVpTRFZTR0ZvTnpneEk5NmhFR0t0YTRUYzFRYlBfbHliWmpIMzJ6bVpSV0x6ZWFncV9tdmN3bEJLQXZDNWRSendyaWRNQmVCdTljZVRNRnR4dEFhWkdfMHlxSXhOSGIwSUZwVmIzaThiaw?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-03T07:00:00+00:00", "published_display": "03 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alumis (ALMS) insider-linked entities shift 4.1M shares via in-kind distributions", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxPaDRNZXNEX3dDWHdyRVpyZkhyR2lub0tUdklSUUhXT1lEZEpZQVY0VVpjeW1OdGZfdUd1S0FvZWt0Zk1JZDdiMmZtR2tuNnJhaFZnSkZPOFNkRFM1NlVtLUdnVVJ2eHhTdzNyaUR6d3ExUzJldlY5VjQ1bGJmY3otYXhlSm1Cakg1RkU0akNTS1psSHM5VmR6S2tRRmRqY1ZoRkJjT29jRQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-03T07:00:00+00:00", "published_display": "03 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Phase 3 win positions Alumis (NASDAQ: ALMS) psoriasis pill for 2026 NDA", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxOZjItZFctUFJhWFF0bzNPeUFjRGZZMlRKbnFpcVE3ZFFjTVdxMmt5a3U2cmFZcEJCQUpia0ZSMGJnQ1R6SS1lM18yZkNGOVN6NnlyQ1JvYngwZ3BsSWtPazVNWTIxTC11Q2tPem5JVjVxcDJtSjZpNm95bEhKaHQ3V0MwU2x3MVczbVhnNDczVU00U1ZwdUN1N0I2WWhnYVRl?oc=5", "source_name": "Stock Titan", "published_at": "2026-03-30T07:00:00+00:00", "published_display": "30 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alumis (ALMS) Q4 Loss Of US$92.9 Million Tests Bullish Growth Narrative", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-03-20T07:00:00+00:00", "published_display": "20 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A psoriasis pill hit late-stage goals; Alumis plans U.S. filing in 2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxPRks2MlJ2LWZNcXZjX1pRQ0I4OXUzck5SeXVIWE1ObFViZTUtdkZJeVctdjE0NTBrMWNHQkZTUUZBT0tzdlNzMHlJNU5DS2NTVHA3c0tEM2RBMlM1ejRqMnJuQnNueFdTenltVXNQZW1NWHpmc25VbE55QTBmbW42NzBvc0hIRXhLQ0FuazJSdzlaa2RJcXZIUjFXcDJoYjVCWl9TSUJSRmZ4XzFCdVVOTEEyOWN4UW10R1I0bzJkLW8?oc=5", "source_name": "Stock Titan", "published_at": "2026-03-19T07:00:00+00:00", "published_display": "19 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Assessing Alumis (ALMS) Valuation After A Strong Multi\u2011Month Share Price Run", "summary": "", "url": "https://news.google.com/rss/articles/CBMijAFBVV95cUxNeW5zNW5sUlF4SHJTVWtkVVBMc3k1ZHItclFDcnlxV3VSaTA0NUdhcW9BdUdvcXNCNS16T3VqbDNwd0o2MmRJTDJtN2VlZkI3emR3bHFHemxRb1d0VVc5SmRVb1RZdldFYTducG4wWndTRWxDUUxQRFN2WG1iT2lTcmNaUjdEOUNGdXhlVg?oc=5", "source_name": "Market source", "published_at": "2026-03-10T07:00:00+00:00", "published_display": "10 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alumis (ALMS) Valuation Check After Strong Multi\u2011Month Share Price Momentum", "summary": "", "url": "https://news.google.com/rss/articles/CBMihwFBVV95cUxObTV2U1VJSkRCaGZfWHlSM0VTdEdWNzFtZl8tNmxWQW11TWVFSDBUVjNhdWZ2OHBLNzdDUFd4UmJhdWRscGJEeENJQTBZLXBlRldJUU1Ya2VKSHluM2k5TEtvdTNXNHZodVVvQkxyX1ktMXpqSDFBV3laQnA1NVdkQkZSekVHWjg?oc=5", "source_name": "Market source", "published_at": "2026-02-07T08:00:00+00:00", "published_display": "07 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alumis Ownership Shifts As Shelf Filing And Conferences Shape Outlook", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-02-06T08:00:00+00:00", "published_display": "06 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alumis (ALMS) Is Up 22.0% After Phase 3 Psoriasis Win And $300 Million Equity Raise", "summary": "", "url": "https://news.google.com/rss/articles/CBMid0FVX3lxTFBIc1loYjE5bS0wZUZKa3VkSVdKX0dvNGFkRVI5UkhHSzBlYks3WnZ6SFFoVzd3dktla1FoSm5LdHR1Q2xOSHFSOGlDQWM4VUdqejV5Mkd6YS04YVZnZXRVNlpaMVhwSjRjNm9maDF1UHJGQ1Z6UHRF?oc=5", "source_name": "Market source", "published_at": "2026-01-18T08:00:00+00:00", "published_display": "18 Jan 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alumis Inc. Stock (ALMS) Opinions on Phase 3 Trial Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxNMVZQeHQ4R2hubjQyWFdOcWE0R3NkSzdaNG44NEVXcTdMc0x2bWRpeG5wY3haamMyZDJOVzBsd05GdE1vSTZXaXpXRm51OFlCUl92a1FHOWF2LXFwSlk4MXpHV1R1Q0dJaVFFUERKbVdnZkFrMXFEZ1lRSlQ2ZmducHEzcnJ6dFdXcnV1UTd4ZDVkbGV3bjAzcjZZaw?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-01-13T08:00:00+00:00", "published_display": "13 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Assessing Alumis (ALMS) Valuation After Positive Phase 3 Psoriasis Data And Strong Share Price Momentum", "summary": "", "url": "https://news.google.com/rss/articles/CBMijwFBVV95cUxQZ1o3RFdlRWRtdmhFYWxrQWREREtiZ21sREc3MF9SMmlMTlhmSWV2SVZKcDU5YzZVN2hES0Z2UzNrWXZobVlSbXJfV3h4aUZJSDllcGd6amZTTE03WnBza3d2RU1yM19aZ2pzMjZoXzYwY1ZpazRFZUtpa25fWjlDZEJyWDBGZXMzQzh6S2JwUQ?oc=5", "source_name": "Market source", "published_at": "2026-01-08T08:00:00+00:00", "published_display": "08 Jan 2026 08:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Alumis Stock Spiked Almost 100% Yesterday", "summary": "", "url": "https://news.google.com/rss/articles/CBMijwFBVV95cUxPdlVibDhuMVl3WEd0dEdZekltSUZLcjVENXUyeTZpV09xTUhnWDBFU2pReEtOZ0tNdE1Kd3A2SHlFU09leEc5MjVlbmdxeldDUFVTNFlHSWxEbGJ3SzRjb3BsN3B3LWtLUTNvM3I0amY1cEkwTkFkS1c4R2xPblRyVnc0TlRZckF3ZUd4cHBCRQ?oc=5", "source_name": "TIKR.com", "published_at": "2026-01-07T08:00:00+00:00", "published_display": "07 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alumis Stock Hits Record High As Wall Street Cheers Phase 3 Psoriasis \u2018Win\u2019 \u2014 Analysts See Best-In-Class Potential", "summary": "", "url": "https://news.google.com/rss/articles/CBMihAJBVV95cUxPU2txZzUtT2tLWGgxVThtZU1wU1BGMDRic0JUUmxwbEtfdTdpcHJrM21Sd2xTZWhKbC1Hc1hsVVI1Z0EwWGZZZ3VqbS01X1VDMUQzRy1XVEptZm82bl9fV2pDajFZSlEzLXJKU212WUtzd0ItN2RRcEN6VG8xclhSc0R2ajZ3cE5Ha2VhR0xNQS0xbmVjTW41N09RVWVhLWNzRUt1bG54VE9TVUdWTHFQMTV6b25rb0xzTXBHVld3Wjd4ZXhZY1l5SDAyOXp0aXpFLTNsck5SSlRYcW1mZDVMRDJXbTBTVWtndDlSMVA3VmYxVlpIU0FTS1p6NHFrTnlGdUdiUw?oc=5", "source_name": "Stocktwits", "published_at": "2026-01-06T08:00:00+00:00", "published_display": "06 Jan 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biotech Alumis plans $175M stock sale in new public offering", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxQYVNEc3F5TXZfN3g5U2lIZnRJQUZlSXB5WS1GaWNxX1RQakR3QTVFbGJnX1F2NGs1RzBsYUF1bVJUMFRLeE1JTUU3b1REZk16SjRHXzE2RW9PUVY3Y3FKTmVodWdLQXhyZzQ1aVMtNnIwTWxHa3lybkk0WTM5TmtVMVlRVHI3RE9xOUpNbHlWMWRmc05zT193Z0FSMlhwbW9GN3RSdW9xYk1Xdw?oc=5", "source_name": "Stock Titan", "published_at": "2026-01-06T08:00:00+00:00", "published_display": "06 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxNZXlTZHFHZVNxMktqZ0hVNURmdE1hUFpZZnlfdEVhMnVla2EyTWN6b2YwNkVhNllxUy1Bczl2a0ZUNk04Q3oyTEZSajdpMnFDVXJfRTlfLUdHQ05uS3FQZkhNWkJ0MDFENDJvRXR0ZGV1RDlYVmdWem96V29NeTg4YWRZWGNoMzM1emRoSExJbXdwZnJIWHpsYjVnT0FQVHZtUW5iVg?oc=5", "source_name": "Market source", "published_at": "2026-03-30T07:00:00+00:00", "published_display": "30 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "With EPS Growth And More, Puma Biotechnology (NASDAQ:PBYI) Makes An Interesting Case", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-12-09T08:00:00+00:00", "published_display": "09 Dec 2025 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 109, "total_relevant": 63, "sentiment_summary": {"positive": 29, "negative": 4, "neutral": 30, "score": 59, "total": 63, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 74, "events": [{"event": "general", "label": "Market update", "weight": 13.75, "count": 25}, {"event": "earnings", "label": "Earnings", "weight": 11.69, "count": 23}, {"event": "analyst", "label": "Analyst action", "weight": 5.5, "count": 10}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 1.65, "count": 3}, {"event": "deals", "label": "Deals and strategy", "weight": 0.55, "count": 1}, {"event": "guidance", "label": "Guidance", "weight": 0.55, "count": 1}], "positive_events": 29, "negative_events": 4}, "market_context": {"has_market_context": true, "latest_close": 23.41, "latest_week": "2026-06-19", "one_week_move": -3.1, "four_week_move": 6.3, "twelve_week_move": -5.6, "trend_signal": "1", "trend_label": "Trend active", "trend_tone": "positive", "market_dynamics": -0.878621, "market_dynamics_buy_signal": false, "relative_strength": 39.451603, "fair_value_gap": 107.0, "fair_value_label": "Materially above fair value", "fair_value_tone": "negative", "expectation_direction": "undecided", "expectation_probability": 46.3576, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-3.1% over one week, +6.3% over four weeks, trend active, and materially above fair value."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 67, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Market source", "count": 13}, {"label": "Stock Titan", "count": 10}, {"label": "simplywall.st", "count": 5}, {"label": "Moomoo", "count": 4}, {"label": "GuruFocus", "count": 3}, {"label": "TradingKey", "count": 2}, {"label": "Simply Wall Street", "count": 2}, {"label": "Benzinga", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 56}, {"label": "Industry context", "count": 7}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 25}, {"label": "Earnings", "count": 23}, {"label": "Analyst action", "count": 10}, {"label": "Regulatory and legal", "count": 3}, {"label": "Deals and strategy", "count": 1}, {"label": "Guidance", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "59/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "74/100 classification confidence."}, {"label": "Company focus", "value": "56", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "0", "tone": "neutral", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend active", "tone": "positive", "text": "-3.1% over one week, +6.3% over four weeks, trend active, and materially above fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Alumis | 4: Statement of changes in beneficial ownership of securities-10% Owner Foresite Capital Management VI LLC"}], "updated_at": "2026-06-22T23:44:29.729923+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}